Evidence map›Paper›PMID 40272257›Full record

ReviewDiabetes2025

Accelerating Medicines Partnership in Type 2 Diabetes and Common Metabolic Diseases: Collaborating to Maximize the Value of Genetic and Genomic Data.

Maria C Costanzo, Beena Akolkar, Melina Claussnitzer, Jose C Florez, Anna L Gloyn, Struan F A Grant, Klaus H Kaestner, Alisa K Manning, Karen L Mohlke, Stephen C J Parker and 12 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Maria C CostanzoPrograms in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA.
Beena AkolkarNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Melina ClaussnitzerBroad Diabetes Initiative and Novo Nordisk Foundation Center for Genomic Mechanisms of Disease, Broad Institute of MIT and Harvard, Cambridge, MA.
Jose C FlorezPrograms in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA.
Anna L GloynDepartment of Pediatrics, Department of Genetics, and Stanford Diabetes Research Center, Stanford School of Medicine, Stanford University, Palo Alto, CA.
Struan F A GrantCenter for Spatial and Functional Genomics, Children's Hospital of Philadelphia, Philadelphia, PA.
Klaus H KaestnerDepartment of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Alisa K ManningPrograms in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA.
Karen L MohlkeDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Stephen C J ParkerGilbert S. Omenn Department of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI.
Paul M TitchenellInstitute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Miriam S UdlerPrograms in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA.
Melissa A JonesFoundation for the National Institutes of Health, North Bethesda, MD.
Tania N KamphausFoundation for the National Institutes of Health, North Bethesda, MD.
Rachel A FischerFoundation for the National Institutes of Health, North Bethesda, MD.
Mark I McCarthyWellcome Centre for Human Genetics, University of Oxford, Oxford, U.K.
Melissa R MillerInternal Medicine Research Unit, Pfizer Research and Development, Pfizer, Cambridge, MA.
Michael BoehnkeGilbert S. Omenn Department of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI.
AMP T2D Consortium
AMP CMD Consortium
Jason FlannickPrograms in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA.
Noël P BurttPrograms in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA.ORCID 0009-0006-4893-7945

Funding

VIRAL VECTOR COREP30DK019525 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI DOUGLAS J EPSTEIN · 1986 to 2026
$48.3M
The Human Pancreas Analysis Program for Type 2 DiabetesU01DK123594 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Robert Babak Faryabi, KLAUS H KAESTNER · 2019 to 2026
$25.0M
Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DAVID P OLSON · 2013 to 2026
$24.3M
The next iteration of the AMP-T2D Knowledge PortalUM1DK105554 · NIDDK · BROAD INSTITUTE, INC. · PI BOEHNKE, MICHAEL L, BURTT, NOEL P · 2020 to 2025
$18.5M
Targeted Genetic Analysis of T2D and Quantitative TraitsR01DK072193 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KAREN L. MOHLKE · 2005 to 2026
$11.3M
Bridging the gap between type 2 diabetes GWAS and therapeutic targetsUM1DK126185 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CLAUSSNITZER, MELINA C, GLOYN, ANNA LOUISE · 2020 to 2024
$9.5M
Genome Wide Association Study for Childhood ObesityR01HD056465 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI GRANT, STRUAN F A · 2008 to 2024
$9.5M
Functional Interrogation of T2D-associated genes in human stem cell-derived models and miceUM1DK126194 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI GRANT, STRUAN F A, KAESTNER, KLAUS H · 2020 to 2024
$8.8M
Genetic epidemiology of rare and regulatory variants for metabolic traitsR01DK093757 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KAREN L. MOHLKE · 2011 to 2026
$8.2M
Identifying Genes for Type 2 Diabetes:FUSIONR01DK062370 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BOEHNKE, MICHAEL L, SCOTT, LAURA J. · 2003 to 2025
$6.7M
The role of senescent beta cells in T1D and T2DU01DK134995 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI KAESTNER, KLAUS H · 2022 to 2025
$2.8M
Identifying variants causal for Type 2 Diabetes in Major human populationsU01DK085545 · NIDDK · UNIVERSITY OF OXFORD · PI CHAN, JULIANA CN, EBRAHIM, SHAH BRIAN · 2009 to 2013
$2.8M
Medical Research Council MR/L020149/1National Institute of Child Health and Human Development R01HD056465NICHD NIH HHS R01 HD056465NIDDK NIH HHS P30 DK019525NIDDK NIH HHS P30 DK020572NIDDK NIH HHS R01 DK062370NIDDK NIH HHS R01DK062370NIDDK NIH HHS R01 DK072193NIDDK NIH HHS R01DK072193NIDDK NIH HHS R01 DK093757NIDDK NIH HHS R01DK093757NIDDK NIH HHS R01 DK125497NIDDK NIH HHS R01DK125497NIDDK NIH HHS U01 DK085545NIDDK NIH HHS U01DK085545NIDDK NIH HHS U01 DK105535NIDDK NIH HHS U01DK105535NIDDK NIH HHS U01 DK123594NIDDK NIH HHS U01DK123594NIDDK NIH HHS U01 DK134995NIDDK NIH HHS U01DK134995NIDDK NIH HHS UM1 DK105554NIDDK NIH HHS UM1DK105554NIDDK NIH HHS UM1 DK126185NIDDK NIH HHS UM1DK126185NIDDK NIH HHS UM1 DK126194NIDDK NIH HHS UM1DK126194Novo Nordisk Fonden NNF21SA0072102Wellcome TrustWellcome Trust 090532Wellcome Trust 095101Wellcome Trust 098381Wellcome Trust 106130Wellcome Trust 200837Wellcome Trust 203141Wellcome Trust 212259
6 · The paper itself

Abstract

In the last two decades, significant progress has been made toward understanding the genetic basis of type 2 diabetes. An important supporter of this research has been the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), most recently through the Accelerating Medicines Partnership Program for Type 2 Diabetes (AMP T2D) and Accelerating Medicines Partnership Program for Common Metabolic Diseases (AMP CMD). These public-private partnerships of the National Institutes of Health, multiple biopharmaceutical and life sciences companies, and nonprofit organizations, facilitated and managed by the Foundation for the National Institutes of Health, were designed to improve understanding of therapeutically relevant biological pathways for type 2 diabetes. On the occasion of NIDDK's 75th anniversary, we review the history of NIDDK support for these partnerships, which saw the convergence of research directions prioritized by academic consortia, the pharmaceutical industry, and government funders. Although the NIDDK was not the sole originator or funder of these efforts, its support and leadership have been pivotal to the partnerships' success and have enabled their research to be broadly accessible through the AMP Common Metabolic Diseases Knowledge Portal (CMDKP) and the AMP Common Metabolic Diseases Genome Atlas (CMDGA). Findings from AMP CMD align with NIDDK's mission to conduct research and share results with the goal of improving health and quality of life. ARTICLE HIGHLIGHTS: The Accelerating Medicines Partnership Program for Type 2 Diabetes (AMP T2D) and Accelerating Medicines Partnership Program for Common Metabolic Diseases (AMP CMD) were created to accelerate the translation of genetic and genomic data into knowledge about the biology of disease. Their goal was to gain a better understanding of the mechanisms underlying types 1 and 2 diabetes and prediabetes, obesity, cardiovascular disease, kidney disease, and nonalcoholic steatohepatitis. This work identified multiple genes and pathways underlying these diseases. The findings of AMP T2D and AMP CMD have implications for drug development and improved risk prediction, diagnosis, and treatment for common metabolic diseases.

Indexed as

Diabetes Mellitus, Type 2GenomicsMetabolic DiseasesHumansNational Institute of Diabetes and Digestive and Kidney Diseases (U.S.)Public-Private Sector PartnershipsUnited States

Identifiers

PMID40272257
PMCPMC12185966

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.